ORCID as entered in ROS

Select Publications
2020, 'Additive and Synergistic Cardiovascular Disease Risk Factors and HIV Disease Markers' Effects on White Matter Microstructure in Virally Suppressed HIV', Journal of Acquired Immune Deficiency Syndromes, 84, pp. 543 - 551, http://dx.doi.org/10.1097/QAI.0000000000002390
,2020, 'Brain amyloid in virally suppressed HIV-associated neurocognitive disorder', Neurology Neuroimmunology and Neuroinflammation, 7, pp. e739, http://dx.doi.org/10.1212/NXI.0000000000000739
,2020, 'HIV-associated neurocognitive disorder (HAND) in people living with HIV in Malaysia: Results from the malaysian HIV and aging (MHIVA) study', International Journal of Infectious Diseases, 101, pp. 292 - 293, http://dx.doi.org/10.1016/j.ijid.2020.09.764
,2019, 'Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm', Journal of Neurovirology, 25, pp. 710 - 721, http://dx.doi.org/10.1007/s13365-018-0706-5
,2019, 'Could excess body weight be good for cognitive health in chronic HIV infection?', Neurology, 93, pp. 95 - 96, http://dx.doi.org/10.1212/WNL.0000000000007769
,2019, 'How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection?', European Geriatric Medicine, 10, pp. 227 - 238, http://dx.doi.org/10.1007/s41999-019-00164-6
,2019, 'HIV brain latency as measured by CSF BcL11b relates to disrupted brain cellular energy in virally suppressed HIV infection', AIDS, 33, pp. 433 - 441, http://dx.doi.org/10.1097/QAD.0000000000002076
,2019, 'Comorbid depression and apathy in HIV-associated neurocognitive disorders in the era of chronic HIV infection', , 165, pp. 71 - 82, http://dx.doi.org/10.1016/B978-0-444-64012-3.00006-X
,2019, 'Processing Emotional Information in Alzheimer's Disease: Effects on Memory Performance and Neurophysiological Correlates (vol 14, pg 104, 2002)', DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 48, pp. 220 - 220, http://dx.doi.org/10.1159/000503763
,2018, 'Brain atrophic signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection', AIDS, 33, pp. 55 - 66, http://dx.doi.org/10.1097/QAD.0000000000002042
,2018, 'Chronic Human Immunodeficiency Virus Infection With and Without Comorbidities Appears to Converge Toward Early Pathological Brain Aging', Biological Psychiatry Cognitive Neuroscience and Neuroimaging, 3, pp. 820 - 821, http://dx.doi.org/10.1016/j.bpsc.2018.08.005
,2018, 'Utility of Using the Montreal Cognitive Assessment (MoCA) as a Screening Tool for HIV-Associated Neurocognitive Disorders (HAND) In Multi-Ethnic Malaysia', AIDS and Behavior, 22, pp. 3226 - 3233, http://dx.doi.org/10.1007/s10461-018-2073-x
,2018, 'No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts', AIDS, 32, pp. 985 - 997, http://dx.doi.org/10.1097/QAD.0000000000001778
,2018, 'The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy', Pathology, 50, pp. 313 - 316, http://dx.doi.org/10.1016/j.pathol.2017.10.017
,2018, 'Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy', AIDS, 32, pp. 35 - 48, http://dx.doi.org/10.1097/QAD.0000000000001685
,2018, 'Covertly active and progressing neurochemical abnormalities in suppressed HIV infection', Neurology Neuroimmunology and Neuroinflammation, 5, pp. &na, http://dx.doi.org/10.1212/NXI.0000000000000430
,2017, 'HIV-related cognitive decline despite viral suppression and complex confounds in American women', Neurology, 89, pp. 1540 - 1541, http://dx.doi.org/10.1212/WNL.0000000000004503
,2017, 'HIV-Associated neurocognitive disorders: A global perspective', Journal of the International Neuropsychological Society, 23, pp. 860 - 869, http://dx.doi.org/10.1017/S1355617717001102
,2017, 'Determining optimal impairment rating methodology for a new HIV-associated neurocognitive disorder screening procedure', Journal of Clinical and Experimental Neuropsychology, 39, pp. 753 - 767, http://dx.doi.org/10.1080/13803395.2016.1263282
,2017, 'Does HIV prematurely age the brain?', Lancet HIV, 4, pp. e380 - e381, http://dx.doi.org/10.1016/S2352-3018(17)30108-X
,2017, 'Erratum to: White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration (Journal of NeuroVirology, (2017), 23, 4, (539-547), 10.1007/s13365-017-0524-1)', Journal of Neurovirology, 23, pp. 548 - 549, http://dx.doi.org/10.1007/s13365-017-0542-z
,2017, 'White matter measures are near normal in controlled HIV infection except in those with cognitive impairment and longer HIV duration', Journal of Neurovirology, 23, pp. 539 - 547, http://dx.doi.org/10.1007/s13365-017-0524-1
,2017, 'Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use', Current HIV AIDS Reports, 14, pp. 83 - 92, http://dx.doi.org/10.1007/s11904-017-0349-9
,2017, 'Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity', PLOS ONE, 12, http://dx.doi.org/10.1371/journal.pone.0171887
,2017, 'Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression', Plos One, 12, pp. e0174613, http://dx.doi.org/10.1371/journal.pone.0174613
,2017, 'Cognitive Change Trajectories in Virally Suppressed HIV-Infected Individuals Indicate High Prevalence of Disease Activity', PLoS One, 12, pp. e0171887, http://dx.doi.org/10.1371/journal.pone.0171887
,2016, 'Reduced cellular energy as a potential marker of HIV brain latency related neuropathogenesis: a pilot study', JOURNAL OF NEUROVIROLOGY, 22, pp. S76 - S77, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000394093700158&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2016, 'A Screening Strategy for HIV-Associated Neurocognitive Disorders That Accurately Identifies Patients Requiring Neurological Review', Clinical Infectious Diseases, 63, pp. 687 - 693, http://dx.doi.org/10.1093/cid/ciw399
,2016, 'Short communication: Do cytomegalovirus antibody levels associate with age-related syndromes in HIV patients stable on antiretroviral therapy?', AIDS Research and Human Retroviruses, 32, pp. 567 - 572, http://dx.doi.org/10.1089/aid.2015.0328
,2016, 'Identifying neurocognitive decline at 36 months among HIV-positive participants in the CHARTER cohort using group-based trajectory analysis', Plos One, 11, pp. e0155766, http://dx.doi.org/10.1371/journal.pone.0155766
,2016, 'Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder', AIDS, 30, pp. 591 - 600, http://dx.doi.org/10.1097/QAD.0000000000000951
,2016, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of Neurovirology, 22, pp. 56 - 65, http://dx.doi.org/10.1007/s13365-015-0368-5
,2016, 'Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials', BMC NEUROLOGY, 16, http://dx.doi.org/10.1186/s12883-016-0527-1
,2016, 'The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review', CNS Drugs, 30, pp. 53 - 69, http://dx.doi.org/10.1007/s40263-015-0302-7
,2015, 'Advancing research in NeuroAIDS using collaboration and public data sharing', BMC Medical Genomics, 8, http://dx.doi.org/10.1186/s12920-015-0150-9
,2015, 'Initiation of antiretroviral therapy in early asymptomatic HIV infection', New England Journal of Medicine, 373, pp. 795 - 807, http://dx.doi.org/10.1056/NEJMoa1506816
,2015, 'The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults', Journal of NeuroVirology, http://dx.doi.org/10.1007/s13365-015-0368-5
,2015, 'HIV eradication symposium: will the brain be left behind?', Journal of Neurovirology, 21, pp. 322 - 334, http://dx.doi.org/10.1007/s13365-015-0322-6
,2015, 'Peripheral blood mononuclear cells HIV DNA levels impact intermittently on neurocognition', Plos One, 10, pp. e0120488, http://dx.doi.org/10.1371/journal.pone.0120488
,2015, 'APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - A cross-sectional observational study', BMC Neurology, 15, pp. 51, http://dx.doi.org/10.1186/s12883-015-0298-0
,2015, 'Editorial commentary: Should longitudinal multisite studies become the new standard for investigating neurocognitive functions in HIV infection?', Clinical Infectious Diseases, 60, pp. 481 - 482, http://dx.doi.org/10.1093/cid/ciu863
,2015, 'HIV infection and obstructive sleep apnea: Why epidemiological data are needed', Journal of Applied Physiology, 118, pp. 248 - 249, http://dx.doi.org/10.1152/japplphysiol.00989.2014
,2015, 'Lessons to be learned from the largest study of cognition in American women with HIV disease', Neurology, 84, pp. 220 - 221, http://dx.doi.org/10.1212/WNL.0000000000001166
,2015, 'Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial', HIV MEDICINE, 16, pp. 97 - 108, http://dx.doi.org/10.1111/hiv.12238
,2015, 'O4‐10‐02: Cross‐cultural differences in instrumental activities of daily living (IADL): Translations and adaptations of the amsterdam iadl questionnaire', Alzheimer's & Dementia, 11, http://dx.doi.org/10.1016/j.jalz.2015.07.400
,2014, 'Primary HIV infection alters brain neurochemistry, but does antiretroviral treatment help?', Neurology, 83, pp. 1588 - 1589, http://dx.doi.org/10.1212/WNL.0000000000000947
,2014, 'Symptoms of depression and rates of neurocognitive impairment in HIV positive patients in Beijing, China', Journal of Affective Disorders, 162, pp. 89 - 95, http://dx.doi.org/10.1016/j.jad.2014.03.038
,2014, 'HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research', Journal of NeuroVirology, 20, pp. 258 - 268, http://link.springer.com/article/10.1007/s13365-014-0242-x
,2014, 'Is the HIV dementia scale a reliable tool for assessing HIV-relatedneurocognitive decline?', Journal of AIDS and Clinical Research, 5, http://dx.doi.org/10.4172/2155-6113.1000269
,2014, 'The effects of HIV and aging on brain functions: Proposing a research framework and update on last 3 years' findings', Current Opinion in HIV and AIDS, 9, pp. 355 - 364, http://dx.doi.org/10.1097/COH.0000000000000078
,